Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Etidronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 5/20 | 0.41 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.33 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.41 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | PGK2 | P07205 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etidronic Acid SCHEMBL5933440 | 0.94 | LMNA (0.53) | LMNAKDM4ECYP2C19KMT2AFDPS | |
| Etidronic Acid SCHEMBL5338103 | 0.88 | LMNA (0.63) | LMNAKDM4ECYP2C19KMT2AFDPS | |
| Etidronic Acid SCHEMBL4136699 | 0.88 | LMNA (0.48) | LMNAKDM4ECYP2C19KMT2AFDPS | |
| Etidronic Acid SCHEMBL20292659 | 0.82 | LMNA (0.48) | LMNAKDM4ECYP2C19KMT2AFDPS | |
| Etidronic Acid SCHEMBL11334405 | 0.82 | LMNA (0.48) | LMNAKDM4ECYP2C19KMT2AFDPS | |
| Etidronic Acid SCHEMBL11329561 | 0.82 | LMNA (0.48) | LMNAKDM4ECYP2C19KMT2AFDPS | |
| Etidronic Acid SCHEMBL16321621 | 0.80 | LMNA (0.46) | LMNAKDM4ECYP2C19KMT2AFDPS | |
| Tert-Butanol SCHEMBL30867679 | 0.80 | SLC34A1 (0.53) | LMNAKDM4ECYP2C19KMT2AFDPS | |
| Etidronic Acid SCHEMBL10957062 | 0.79 | LMNA (0.77) | LMNAKDM4ECYP2C19KMT2AFDPS | |
| Etidronic Acid SCHEMBL157065 | 0.78 | LMNA (0.47) | LMNAKDM4ECYP2C19KMT2AFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-20250161187-A1 | ORAL CARE COMPOSITION COMPRISING ENZYMES | NOVOZYMES A/S (DK) | 2025-05-22 | — | — | US | disclosed |
| EP-4547210-A1 | MUTANASES AND ORAL CARE COMPOSITIONS COMPRISING SAME | Novozymes A/S (DK) | 2025-05-07 | — | — | EP | disclosed |
| CN-119899217-A | Metal complex with anti-tumor immune activity, preparation method and application thereof | 南京师范大学 | 2025-04-29 | — | — | CN | disclosed |
| CN-116492362-B | Traditional Chinese medicine composition for preventing and treating Alzheimer disease and/or osteoporosis, preparation method and application | 中国药科大学 | 2025-04-29 | — | — | CN | disclosed |
| US-20250127699-A1 | One Pot Process for Preparing 'Grit-Free' Solid Cleansing Compositions | GALAXY SURFACTANTS LTD. (IN) | 2025-04-24 | — | — | US | disclosed |
| EP-4541340-A1 | A ONE POT PROCESS FOR PREPARING 'GRIT-FREE' SOLID CLEANSING COMPOSITIONS | Galaxy Surfactants Ltd. (IN) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025027043-A1 | HAIR COMPOSITION COMPRISING HYALURONIC ACID, A NONIONIC SURFACTANT AND A PERFUMING SUBSTANCE | L'OREAL (FR) | 2025-02-06 | — | — | WO | disclosed |
| CN-114174263-B | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-114159454-A | Traditional Chinese medicine composition for preventing and treating Alzheimer disease and/or osteoporosis, preparation method and application | 中国药科大学 | 2022-03-11 | — | — | CN | disclosed |
| WO-2022043273-A2 | ORAL CARE COMPOSITION COMPRISING A FRUCTANASE | NOVOZYMES A/S (DK) | 2022-03-03 | — | — | WO | disclosed |
| CN-110776892-A | Microemulsion neutral blocking remover | 西安中孚凯宏石油科技有限责任公司 | 2020-02-11 | — | — | CN | disclosed |
| EP-2576778-B1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN RODENTS | UNIV KYOTO (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-9273364-B2 | Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in mammalian organisms | KYOTO UNIVERSITY (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20130137099-A1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN MAMMALIAN ORGANISMS | KYOTO UNIVERSITY (JP) | 2013-05-30 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| WO-2010068358-A1 | INHALANT FORMULATIONS COMPRISING A BISPHOSPHONATE AND A PYRAZOLONE DERIVATIVE AND METHODS FOR USING THE SAME | TEIKOKU PHARMA USA, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| US-20100034752-A1 | INHALANT FORMULATIONS COMPRISING A BISPHOSPHONATE AND A PYRAZOLONE DERIVATIVE AND METHODS FOR USING THE SAME | TEIKOKU PHARMA USA | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127699-A1 | One Pot Process for Preparing 'Grit-Free' Solid Cleansing Compositions | DEGS1, SGMS1, LIPA | FDPS 1809/4885CA2 3358/4885THRB 3174/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | FDPS 2455/4885CA2 348/4885THRB 3769/4885 |
| US-20100034752-A1 | INHALANT FORMULATIONS COMPRISING A BISPHOSPHONATE AND A PYRAZOLONE DERIVATIVE AND METHODS FOR USING THE SAME | PTH1R, P2RY6, P2RY1 | FDPS 91/4885CA2 969/4885THRB 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.